Dr. Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke’s Health System, Executive Director of the Cardiometabolic Center Alliance, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, Professor of Medicine at the University of Missouri-Kansas City and the inaugural recipient of the Ben McCallister, MD Endowed Chair in Cardiovascular Research at Saint Luke’s Health System.
Dr. Kosiborod is an internationally-recognized expert in the field of cardiometabolic disease and has authored and co-authored more than 400 peer-reviewed publications.
Dr. Kosiborod has conducted and led numerous national and international clinical trials, many of which have had a significant impact on treatment guidelines and clinical practice. Dr. Kosiborod’s body of work has been central to the elucidation of the impact of SGLT2 inhibition in improving cardiovascular outcomes and survival in various clinical settings, perhaps one of the most important advances in clinical cardiology seen in a generation.